Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 16/20 | 0.56 |
| ▸ | GNA15 | P30679 | 1/20 | 0.56 |
| ▸ | PPARD | Q03181 | 2/20 | 0.48 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.48 |
| ▸ | RXRA | P19793 | 1/20 | 0.48 |
| ▸ | RXRB | P28702 | 1/20 | 0.48 |
| ▸ | CTSA | P10619 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4676448 | 1.00 | FFAR1 (0.56) | FFAR1GNA15PPARDSLC13A5RXRA | |
| SCHEMBL14495982 | 0.85 | FFAR1 (0.61) | FFAR1GNA15PPARDSLC13A5RXRA | |
| SCHEMBL4677328 | 0.82 | FFAR1 (0.54) | FFAR1 | |
| SCHEMBL4677323 | 0.82 | FFAR1 (0.54) | FFAR1 | |
| SCHEMBL6104254 | 0.81 | FFAR1 (0.72) | FFAR1PPARDRXRA | |
| SCHEMBL3555589 | 0.81 | FFAR1 (0.72) | FFAR1PPARDRXRA | |
| SCHEMBL13118213 | 0.80 | FFAR1 (0.85) | FFAR1GNA15 | |
| SCHEMBL3521855 | 0.80 | FFAR1 (0.63) | FFAR1PPARDRXRA | |
| SCHEMBL4802750 | 0.79 | FFAR1 (0.66) | FFAR1 | |
| SCHEMBL4802757 | 0.79 | FFAR1 (0.66) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893582-B1 | Compounds, their pharmaceutical compositions and their use in treating metabolic disorders | AMGEN INC (US) | 2011-12-14 | — | — | EP | claimed |
| US-7465804-B2 | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders | AMGEN INC. (US) | 2008-12-16 | — | — | US | claimed |
| US-20060270724-A1 | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders | AMGEN INC (US) | 2006-11-30 | — | — | US | claimed |
| EP-1893582-B1 | Compounds, their pharmaceutical compositions and their use in treating metabolic disorders | AMGEN INC (US) | 2011-12-14 | — | — | EP | disclosed |
| US-7465804-B2 | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders | AMGEN INC. (US) | 2008-12-16 | — | — | US | disclosed |
| EP-1893582-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE IN TREATING METABOLIC DISORDERS | Amgen, Inc (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006127503-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE IN TREATING METABOLIC DISORDERS | AMGEN INC (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060270724-A1 | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders | AMGEN INC (US) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270724-A1 | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders | IAPP, INSR, GPR119 | FFAR1 931/4885GNA15 3748/4885PPARD 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.